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Since kallikrein was discovered as a vasodilatory substance in
human urine, the kallikrein–kinin system (KKS) has been
considered to play a physiological role in controlling blood
pressure. Gene targeting experiments in mice in which the
KKS has been inactivated to varying degrees have, however,
questioned this role, because basal blood pressures are not
altered. Rather, these experiments have shown that the KKS
has a different and important role in preventing changes
associated with normal senescence in mice, and in reducing
the nephropathy and accelerated senescence-associated
phenotypes induced in mice by diabetes. Other experiments
have shown that the KKS suppresses mitochondrial
respiration, partly by nitric oxide and prostaglandins, and
that this suppression may be a key to understanding how the
KKS influences senescence-related diseases. Here we review
the logical progression and experimental data leading to
these conclusions, and discuss their relevance to human
conditions.
Kidney International (2009) 75, 1019–1030; doi:10.1038/ki.2008.647;
published online 4 February 2009
KEYWORDS: ACE inhibitors; aging; bradykinin; DNA damage; electron
transport chain; oxidative stress
BACKGROUND
Angiotensin-I-converting enzyme and bradykinin
The angiotensin-I-converting enzyme (ACE, also known as
kininase II) is a carboxydipeptidase that removes two amino
acids from the carboxyl terminus of the inactive peptide
angiotensin I and converts it into the active blood pressure-
raising peptide, angiotensin II. ACE also converts the active
blood pressure-lowering kinins, bradykinin (1–9) and kallidin
(1–10), into inactive bradykinin (1–7) and kallidin (1–8)
(Figure 1a). ACE has a 30 times lower Km and 10 times higher
kcat for the kinins than for angiotensin I.
1
A very common insertion/deletion (I/D) polymorphism
of the ACE gene is associated with different relative
plasma levels of the enzyme, ranging from about 0.75–1.0
to 1.25 in I/I, I/D, and D/D individuals.2 The ACE I/D
polymorphism in humans does not significantly affect blood
pressure,3 nor does a modest genetically induced decrease in
expression of the Ace gene (to 0.5 normal) or a modest
increase (to 1.5 normal) affect blood pressure in mice.4
Nevertheless, the two human alleles are associated with
different risks for developing a wide constellation of diseases,
including diabetic nephropathy,5 breast cancer,6–8 prostate
cancer,9,10 gastric cancer,11,12 Alzheimer’s disease,13 Parkin-
son’s disease,14 congestive heart failure,15 myocardial infarc-
tion,16 stroke,17 and retinal macular degeneration.18 In all
these many senescence-associated human disorders, it is the
D allele with its higher levels of ACE that confers the
increased risk.
A clear example of this association is provided by the
demonstration that the D allele is an independent risk factor
for both the onset and progression of nephropathy in type I
diabetic patients.5 This association led to experiments in
which diabetes was induced with streptozotocin (STZ) in
mice having different genetically determined levels of ACE.19
These experiments showed that, when diabetic, mice having
the higher levels of the enzyme (about 1.5 normal)
developed significantly more urinary albumin excretion
than their siblings with normal or reduced (0.5 normal)
levels of ACE. These experiments consequently established a
causative link between genetically increased levels of ACE and
the nephropathy induced by type I diabetes. Yet earlier
experiments with varying degrees of ACE inhibition,20
and computer simulations of the effects of genetically
altering the levels of ACE,21 had shown that such modest
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changes in ACE levels have little effect on the levels
of its products (including the active peptide angiotensin
II), although they change the levels of its substrates
(including the active peptides bradykinin (1–9) and
kallidin (1–10)). This consideration led to the inference
that decreases in the level of the active ACE substrate
bradykinin probably mediate the harmful effects of the ACE
D allele.
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Figure 1 | Components and signaling of the KKS. (a) Biosynthesis and metabolism of kinins. CPM, carboxypeptidase-M; ACE, angiotensin I-
converting enzyme; NEP, neprilysin (endopeptidase 24.11); ECE, endothelin-converting enzyme; red, active peptides; blue, inactive peptides.
(b) Binding of kinins to bradykinin receptors and two intracellular mechanisms for suppression of oxidative metabolism. The thickness of
arrows arising from the kinins indicates the relative potency of each peptide to elevate intracellular calcium concentrations. PIP2,
phosphatidylinositol-4,5-bisphosphate; PI-PLC, phosphatidylinositol-specific phospholipase C; IP3, 1,4,5-inositol triphosphate; ER,
endoplasmic reticulum; PL, phospholipids; PLA2, phospholipase A2.
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The kinins
The kinins, bradykinin and kallidin in humans or bradykinin
and the kallidin-like peptide in rodents, are generated from
kininogens by kallikreins (Figure 1a). Humans have one
kininogen gene; rodents have two closely linked kininogen
genes.22 Kallidin can be converted into bradykinin by a
plasma aminopeptidase. All the kinins are strong agonists of
the bradykinin 2 receptor (B2R, Bdkrb2), although less so of
the B1 receptor (B1R, Bdkrb1). Kininase I (carboxypeptidase-
N) and carboxypeptidase-M remove arginine from the
carboxyl terminus of the kinins and generate their des-Arg
derivatives, which are agonists mainly of B1R. Kininase II (a
synonym for ACE),23 neprilysin (endopeptidase 24.11),23 and
endothelin-converting enzyme24 all remove two amino acids
(Phe and Arg) from the carboxyl terminus of the kinins, and
inactivate them.
Bradykinin B1 and B2 receptors
In mammals, as indicated above, two bradykinin receptors
have been identified: B1R and B2R, both of which are
G protein-coupled receptors with seven transmembrane
domains. Mice deficient in both B1R and B2R have no
contractile response to bradykinin in isolated smooth muscle
tissues, suggesting that there are no other major receptors for
bradykinin, at least in smooth muscle cells.25 The B2R
protein is constitutively expressed in most tissues. Vascular
endothelial cells express B2R abundantly, where it is
functionally linked to activation of endothelial nitric oxide
(NO) synthase (eNOS, Nos3). Expression of B1R is minimal
under normal circumstances, but is induced by inflamma-
tion,26 diabetes,27 ischemia/reperfusion injury,28 and by the
absence of B2R.29 B2R mRNA is expressed in all segments of
the kidney under physiological conditions, and lipopolysac-
charide (LPS) increases this expression. In contrast, no B1R
mRNA levels can be detected in any segments of the kidney
under physiological conditions, although treatment with LPS
induces the expression of B1R mRNA in all renal segments
except the outer medullary collecting ducts.30
The transcriptional regulation of the two receptor genes
differ, although the intracellular signals that follow stimula-
tion of B1R and B2R are quite similar (Figure 1b).31,32
Stimulation of bradykinin receptors by kinins elevates
[Caþ þ ]i by activation of phosphatidylinositol (PI)-specific
phospholipase C (PI-PLC) in Gq-protein-dependent and Gq-
protein-independent ways. Allosteric activation of PI-PLCb
isoforms by Gq/11 proteins and direct tyrosine phosphoryla-
tion of PI-PLCg isoforms by bradykinin receptors33,34 both
play an important role in the bradykinin-induced changes in
[Caþ þ ]i (Figure 1b).
Stimulation of either B1R or B2R increases eNOS activity
and prostacyclin synthesis in endothelial cells, at least partly
by elevating intracellular calcium levels ([Caþ þ ]i).35,36 And
it has recently been shown that bradykinin, kallidin, and
kallidin-like peptide are equipotent at eliciting Caþ þ -
transients by B2R in humans and rodents.37 As the
concentration of kallidin or kallidin-like peptide is much
higher than that of bradykinin in humans38 and rats,39
kallidin and kallidin-like peptide rather than bradykinin may
be the major endogenous agonists of the KKS.
The NO release in response to agonist binding by B1R is
slow in onset, but desensitization of B1R does not occur.40 In
contrast, the NO response of the B2R is rapid40 and agonist-
occupied phosphorylated B2R41 is internalized into endo-
somes in a b-arrestin 2- and clathrin-dependent manner.42,43
This uncouples B2R from the G proteins and desensitizes the
second messenger-mediated signal.42 Interestingly, eNOS also
reversibly translocates from the cell membrane into the cell
cytosol following B2R stimulation or administration of a
calcium ionophore.44 Although the kinins promote B2R
endocytosis, they delay B1R endocytosis, which is clathrin-
dependent but b-arrestin 2-independent.43
In transgenic mice, over expression of B2R results in
hypotension,45 but overexpression of B1R does not change
blood pressure.46 In contrast, the absence of either B2R or
B1R does not change blood pressure,47,48 nor does lack of
both bradykinin B1R and B2R, which abolishes most of
bradykinin signaling.25,49 Furthermore, mice lacking tissue
kallikrein and kininogen-deficient Brown Norway Katholiek
rats have normal blood pressure.50,51 These observations
suggest that the KKS plays only a minor physiological role in
regulating chronic blood pressure in mammals, even though
transient decreases in blood pressure are caused by admin-
istration of kallikrein or the kinins.
Bradykinin and nitric oxide (NO)
The absence of B2R decreases the urinary excretion of stable
metabolites of NO (NO2
 and NO3),52 and lack of both B1R
and B2R reduces fasting plasma NO2
/NO3
 concentration.49
Stimulation of the bradykinin receptors by the kinins
elevates [Caþ þ ]i and activates the Caþ þ -dependent iso-
forms of the NOS (eNOS and neuronal NOS).53,54
Bradykinin through its receptors also leads sequentially to
activation of PI3-kinase, phosphorylation of Akt, and phos-
phorylation of eNOS, which sensitizes it to [Caþ þ ]i.55
Furthermore, B2R forms a complex with eNOS from which
the active enzyme is released following receptor activation.56
Bradykinin also increases the association of heat-shock
protein 90 with eNOS, which is required for NO formation
by eNOS.57
The expression of inducible NOS (the Caþ þ -indepen-
dent isoform of the NOS) is also increased by bradykinin
through both B1R58 and B2R.59 The bradykinin-induced
expression of inducible NOS is dependent on intranuclear
calcium and Akt signaling in rat hepatocytes.59
Lipopolysaccharide causes hypotension in normal rats,
which is diminished by a B2R antagonist.60 Furthermore,
kininogen-deficient rats and mice lacking both B1R and B2R
are resistant to LPS-induced septic shock.25,60 Inducible NOS
mRNA levels are increased by LPS in wildtype, but in mice
lacking both B1R and B2R this increase is diminished.25
Thus, bradykinin plays a role in the development of septic
shock, in part by inducible NOS.
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Together these various studies show that the KKS is
important in controlling NO production through all the
isoforms of NOS. The NO so formed has the potential of
acting on the cells that produced it or on neighboring cells.
Bradykinin and the prostaglandins
Most of the nonsteroidal anti-inflammatory drugs, including
aspirin, indomethacin, ibuprofen, and the more isoform-
specific cyclooxygenase inhibitors, exert their anti-inflamma-
tory effects by inhibiting the formation of arachidonic acid
metabolites, including the prostaglandins (PGs). Bradykinin
acts through its receptors in at least three ways to increase
production of PGs. First, it leads to the Caþ þ -dependent
phosphorylation and translocation into the cell membrane of
cytosolic phospholipase A2.61,62 Second, bradykinin stimu-
lates membrane-associated Caþ þ -independent phospholi-
pase A2.63 Both the Caþ þ -dependent and -independent A2
phospholipases liberate arachidonic acid from membrane
phospholipids. Third, bradykinin leads to the induction of
cyclooxygenase-2,64–66 which converts arachidonic acid into
PGs. The bradykinin-stimulated formation of PGE2 is
inhibited by pertussis toxin,67 suggesting that this response
is mediated by the Gi protein that is associated with the
bradykinin receptors.68 The PGs formed following stimula-
tion of the bradykinin receptors, acting through PG
receptors, mediate some of the effects of the kinins on
vascular tone and on mitochondrial respiration. When kinins
are injected in supra-physiological amounts, they cause
inflammation, pain, and increased vascular permeability,69
at least partly through the PGs. KKS antagonists are therefore
effective for suppressing excessive inflammatory responses.70
Bradykinin and other second messengers
The endothelium-dependent vasodilatory effect of bradyki-
nin is not completely abolished by the simultaneous
administration of NOS inhibitors and cyclooxygenase
inhibitors. However, this unexplained vasodilation is inhib-
ited by blockers of Caþ þ -activated Kþ -channels or high
external [Kþ ], suggesting the presence of an endothelium-
derived hyperpolarizing factor.71 Epoxyeicosatrienoic acids,
P450 epoxygenase metabolites of arachidonic acid, are most
likely candidates for the endothelium-derived hyperpolariz-
ing factor.72
The C-terminal part of B2R interacts with the protein-
tyrosine phosphatase SH2 domain-containing phosphatase-2
(SHP-2), and activates it in rat mesangial cells.73 As the
antimitogenic effect of bradykinin is abolished by transfec-
tion of dominant-negative SHP-2 in mesangial cells,73 it is
possible that bradykinin, acting through SHP-2, plays a role
in controlling the mesangial expansion that occurs in many
glomerular diseases.
Bradykinin, oxidative stress, and senescence
Mitochondrial oxidative respiration is a much more efficient
source of energy than anaerobic glycolysis. However,
oxidative metabolism generates reactive oxygen species,
which can have deleterious effects. Several studies have
shown that NO reversibly suppresses mitochondrial oxidative
metabolism,74,75 in part by inhibiting cytochrome c oxidase, a
key enzyme in electron transport chain.76,77 Recent studies
have also shown that cAMP decreases mitochondrial
respiration by activating NADH-ubiquinone oxidoreductase
activity of complex I and by inhibiting cytochrome c
oxidase.78,79 As bradykinin, acting through B1R and B2R,
stimulates eNOS activity in vascular endothelial cells and
increases cAMP levels in kidney epithelial cells, it is not
surprising that the KKS can influence the level of oxidative
stress. For example, when bradykinin is administered to rats
that were made hyperglycemic with STZ, it reduces their
oxidative stress phenotype, as judged by hydrogen peroxide
and malondialdehyde levels.80 Furthermore, because the
binding of B2R to eNOS, referred to above, is through the
oxygenase domain of the enzyme, the ability of eNOS to
catalyze uncoupled NADPH oxygenation is blocked by B2R,81
suggesting that B2R can affect the generation of reactive
oxygen species by eNOS even without agonist stimulation.
In the kidney, proximal tubular epithelial cells are densely
packed with mitochondria, which supply the energy for the
active transport of sodium ions by Naþ /Kþ ATPase. These
cells are among the most oxygen-using cells of the body, and
are therefore at risk for oxidative damage. It is consequently
again not surprising that several indicators of oxidative
damage are increased in these and other high oxygen-using
cells when the KKS is impaired by the absence of B2R.
Figure 2a illustrates this by showing that lack of B2R greatly
enhanced the accumulation in diabetic mice of lipofuscin-
like intracellular inclusions (an indicator of mitochondrial
damage) in renal proximal tubules.82
Lipofuscins are electron dense substances contained in
autophagolysosomes derived from damaged organelles
(Figure 2b). They are a manifestation of senescence as well
as of oxidative stress.83 Mice lacking the senescence marker
protein-30 have systemic premature senescence, and lipofus-
cin accumulation is observed in their proximal tubular cells
preceded by senescence-associated b-galactosidase activity,84
an established hallmark of aging.85 We have also observed
that the deposition of lipofuscin in the proximal tubule cells
of B2R-null Akita mice aged 12 months is associated with the
presence of senescence-associated b-galactosidase activity
(unpublished observation).
Point mutations and deletions in mitochondrial DNA,
which are also known reflections of aging,86,87 were increased in
the kidney by the absence of B2R even in non-diabetic mice,
although additively more so with diabetes82 (Figure 2b and c).
Transforming growth factor b1 enhances autophagy,88 and
its expression is increased in aged cells89 and in a number of
fibrogenic kidney diseases.90 We have found that the absence
of B2R and/or presence of diabetes enhances the renal
expression of transforming growth factor b1.82 Thus, the
increase in transforming growth factor b1 expression may
play a causative role in lipofuscin accumulation in the kidney
of B2R-null Akita mice.
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EXPERIMENTAL STUDIES ON KKS IN RENAL DISEASES
Diabetic nephropathy
We have described above how genetically increased ACE levels,
which do not change blood pressure or angiotensin II levels,4
nevertheless enhance urinary excretion of albumin in mice with
diabetes induced by STZ.19 In the reverse direction, ACE
inhibition is protective in many models of diabetic nephro-
pathy.91–94 That this protection is mediated in part by
the KKS is strongly suggested by experiments showing that the
beneficial effects of ACE inhibitors were attenuated by a B2R
antagonist in rats that were made diabetic with STZ,91,92 in obese
Zucker diabetic fatty rats,93 and in C57BLKS db/db mice.94
We have found that albuminuria, glomerular sclerosis,
interstitial fibrosis, lipofuscin accumulation in proximal
tubules, and lifespan shortening in Akita diabetic mice are
enhanced by the absence of B2R.82,95 In agreement with these
observations, adeno-associated virus-mediated expression of
the human tissue kallikrein has been shown to mitigate
nephropathy induced by STZ and high-fat diet as assessed by
urinary albumin excretion, histological changes, creatinine
clearance, and urinary osmolarity.96 However, Tan et al.97
have reported that deletion of B2R protects against the
albuminuria and histological changes which develop in
diabetic nephropathy induced by STZ. These opposite results
may be due to the differences in the strains of mice used and/
or in the method of induction of diabetes.
The importance of NO in relation to experimental
diabetic nephropathy is well documented. Thus, L-arginine,
the substrate of the NO synthases, reduces the proteinuria
that develops in STZ-induced diabetic rats.98 Furthermore,
L-NAME, an NOS inhibitor, aggravates the proteinuria and
histological changes that occur in the diabetic nephropathy of
Otsuka Long-Evans Tokushima Fatty rats.99 eNOS deficiency
also accelerates the severity of diabetic nephropathy in
C57BLKS/J db/db mice,100 lepr(db/db) mice,101 and STZ-
treated C57BL/6 mice.102 As bradykinin induces eNOS
activity,40 these observations bear directly on how the KKS
exerts its protective effects.
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Figure 2 | Senescence-associated indices in the kidney of B2R-null and/or Akita diabetic mice. (a) Periodic acid-Schiff-stained kidneys
of 12-month-old male mice (bar¼ 10mm). Note the intracellular pigmented vacuoles in the cytoplasm of the proximal tubular epithelial cells
of the Akita diabetic mice (Ins2 Akita/þ ), and their greater prominence when the diabetic mice also lack B2R (bdkrb2/). (b) Transmission
electron micrograph of a renal proximal tubule cell from a 12-month-old doubly mutant mouse (bar¼ 1 mm). There are numerous
phagolysosomes containing lipid debris with focal lamination (arrows). (c) Frequencies of point mutations in mitochondrial DNA. (d)
Relative proportion of D-17 deletions in mitochondrial DNA.
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Cicaprost, a PGI2 analog, also attenuates the progression
of diabetic renal injury in STZ-treated rats,103 suggesting that
the beneficial effects of the KKS also involve the PG arm of
the system.
Hypertensive glomerulosclerosis and other chronic
fibrogenic kidney diseases
In Dahl salt-sensitive rats, an animal model of salt-sensitive
hypertension, an ACE inhibitor reduced the proteinuria,
urinary excretion of N-acetyl-b-D-glucosaminidase (an in-
dicator of damages in proximal tubules), and renal fibrotic
changes caused by high salt. The protective effects of an
angiotensin II type 1 receptor blocker (ARB) were,
however, much smaller than those of the ACE inhibitor,
despite the same reduction of blood pressure.104 In Ren-2
transgenic rats, an ACE inhibitor or a vasopeptidase inhibitor
significantly reduced tubulointerstitial fibrosis, and this
reduction was annulled by a B2R antagonist.105 Long-term
infusion of rat urinary kallikrein106 or bradykinin107 into
Dahl salt-sensitive rats attenuated their urinary protein
excretion and glomerulosclerosis, despite no changes in
blood pressure. The beneficial effect of infused kallikrein
was attenuated by a B2R antagonist.108 Adenovirus-mediated
human tissue kallikrein gene delivery caused a similar
favorable effect in both Dahl salt-sensitive rats and
Goldblatt hypertensive rats, again without affecting blood
pressure.109,110
In rats with passive Heymann nephritis, an experimental
model of human membranous nephropathy, an ACE
inhibitor exerted antiproteinuric action, which was prevented
by a B2R antagonist.111
Alport syndrome is a hereditary cause of endstage renal
disease (ESRD) due to defects in type IV collagen genes. In
mice lacking the COL4A3 gene, an animal model of Alport
syndrome, an ACE inhibitor reduced the proteinuria and
renal interstitial fibrosis.112 In subsequent experiments, it was
shown that the ACE inhibitor extended the lifespan of the
COL4A3-null mice by 111%, whereas an ARB resulted in
only a 38% prolongation of the lifespan,113 emphasizing the
importance of non-angiotensin II mechanisms in helping
survival of these animals.
Unilateral ureteral obstruction in rodents is a well-
established non-immune inflammatory experimental model
that results in tubulointerstitial fibrosis in the obstructed
kidney. ACE inhibitors,114 and to a lesser extent ARBs,115
prevent the progression of tubulointerstitial fibrosis in this
unilateral ureteral obstruction models. Co-treatment of the
animals with an ACE inhibitor and a NOS inhibitor reversed
the beneficial effect of the ACE inhibitor in the obstructed
kidney.116 Unilateral ureteral obstruction-induced fibrosis is
more severe in B2R-null mice than wild-type mice, and less
severe in the human tissue kallikrein-transgenic rats than in
control Sprague Dawley rats.117 These several experiments
together provide a strong case for the importance of the KKS
in limiting the tubulointerstitial fibrosis caused by unilateral
ureteral obstruction.
Aminoglycoside-induced renal injury
Aminoglycoside antibiotics have been used primarily to
repress infection by aerobic Gram-negative bacteria. They
are, however, notorious for their ototoxicity and nephrotoxi-
city, although how they cause the proximal tubular cell
necrosis that constitutes their renal effects is largely
unknown. However, in this context it is intriguing that the
administration of tissue kallikrein protein118 or tissue
kallikrein-expressing adenovirus119 are both protective
against gentamicin-induced renal injury in rats. NAD(P)H
oxidase activity and superoxide production in the kidney are
elevated by gentamicin treatment.120 Administration of tissue
kallikrein partially reverses these increases,118 indicating that
enhancing KKS activity can reduce gentamicin-induced renal
injury.
Other studies have shown that the NOS substrate
L-arginine prevents gentamicin-induced tubular damage in
rats,121 whereas the NOS inhibitor NG-nitro-L-arginine-
methyl ester increases the damage.121,122 PGI2 overexpression
in renal tubular cells also prevented apoptosis induced by
gentamicin, and decreased the generation of reactive oxygen
species induced by the drug.123 Thus, the protective effect of
tissue kallikrein against gentamicin-induced renal injury is
probably mediated by its ability to increase both NO and
PGI2.
Ischemia-reperfusion injury
The angiotensin-I-converting enzyme inhibitors markedly
and consistently reduce the tissue injury that occurs in
ischemic acute renal failure (iARF), including the tubular
necrosis, loss of endothelium-dependent vasorelaxation, and
excretory dysfunction.124,125 In contrast, it is still debatable
whether ARBs have any beneficial effects on the tissue
damage caused by iARF.126,127 There is agreement, however,
that ACE inhibitors are more effective than ARBs in
protecting against ischemia-reperfusion injury.127–130
Furthermore, a B2R antagonist and NOS blocker markedly
attenuate the protective effects of the ACE inhibitors.128,129
These observations support the concept that, in many
contexts, ACE inhibitors are beneficial more by inhibiting
the inactivation of the kinins than by suppressing angiotensin
II formation.
Recent studies are beginning to provide a more detailed
explanation for this protection. Thus, it is now known
that ischemia-reperfusion injuries are associated with
mitochondrial Ca2þ overload consequent to a burst of
reactive oxygen species, which together trigger the opening
of mitochondrial permeability transition pores leading to cell
apoptosis.131 This opening of mitochondrial pores is
suppressed by bradykinin.132 As NO, a second messenger of
both bradykinin receptors, reversibly suppresses mitochon-
drial oxidative metabolism,74,75 it is possible that the KKS can
reduce or prevent the burst of reactive oxygen species.
In contrast to the consensus that ACE inhibitors have
beneficial effects on ischemia-reperfusion injury, in part
mediated by the KKS, there are conflicting reports on the
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effects of administered bradykinin on iARF. Thus, exogenous
supplementation of bradykinin has been reported to
aggravate iARF,133 yet suppression of the endogenous
KKS49 is detrimental to functional recovery after iARF. These
findings suggest that physiological levels of bradykinin
produced endogenously, but not the presumably higher
levels achieved with exogenously administered bradykinin,
play a beneficial role in iARF. In agreement with this
interpretation, adenovirus-mediated gene transfer of tissue
kallikrein has been shown to protect against ischemic stroke
in rats.134 Similarly, transgenic expression of tissue kallikrein
in mice attenuates ischemic cardiac damage,135 whereas
knocking out tissue kallikrein aggravates the damage.28
We have found that lack of B2R alone or lack of both
receptors, B1R and B2R, aggravates the renal morphological
and functional damages and mortality following iARF.49
Furthermore, the absence of both B1R and B2R had more
detrimental effects than deficiency in B2R only, showing that
both B1R and B2R are protective in iARF.49 As NO donors
attenuate136 and NOS inhibitors aggravate tissue damage in
iARF,137,138 endothelium-derived NO is most likely to be one
of the mediators of the beneficial effect of bradykinin. In
addition, earlier studies have shown that prostaglandins E1,
E2, and I2139–143 are protective in mitigating renal injury
caused by iARF, suggesting that phospholipase A2-derived
products are involved in bradykinin-induced protection
following iARF.
Autosomal dominant polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD)
accounts for 10% of cases of ESRD. In the heterozygous
cystic Han:Sprague-Dawley-cy rat, which is an animal model
of ADPKD, urinary kallikrein and bradykinin levels are
increased compared with age-matched controls.144 ACE
inhibition significantly reduces the albuminuria and prevents
the enlargement of kidney size and decline in glomerular
filtration rate, independently of its effects on blood
pressure,145–148 suggesting that the KKS has a protective role
in this ADPKD model. However, it has been reported that a
B2R antagonist significantly reduced proteinuria and albu-
minuria in this model,148 and in human ADPKD patients, the
KKS system is not activated.144
Chronic renal failure
Irrespective of their etiology, most renal diseases eventually lead
to a reduction in the number of nephrons and to insufficiency
of renal excretory function and chronic renal failure (CRF).
The rate of decline in creatinine clearance accelerates as the
absolute value of creatinine clearance is reduced, suggesting
overload on the remaining nephrons (‘hyperfiltration theo-
ry’).149 In the 5/6 nephrectomy animal model of CRF, ACE
inhibitors,118,150 adenovirus virus-mediated tissue kallikrein
gene delivery,151 or adeno-associated virus delivery,152 all
decelerate the decline in renal function. However, whether a
B2R antagonist abrogates the beneficial efficacy of ACE
inhibitors in this 5/6 renal mass reduction model is
debatable.118,150 Nevertheless, as renal pathology and mortality
in this model are both exaggerated by eNOS deficiency,153 it is
most likely that changes in eNOS activity are partly responsible
for the beneficial effect of KKS in CRF.
RELEVANCE OF THE KKS TO RENAL DISEASES IN HUMANS
Studies of mice in which genes have been knocked out have
proved invaluable in determining the role of many genes in
mammals. However, the common human diseases, such as
diabetes and hypertension, do not appear to be prevalent
because of the complete absence of any gene function. Rather
they appear to be due to a variety of combinations of genetic
differences that individually have relatively small quantitative
effects.154 Furthermore, humans are genetically more hetero-
genous than inbred experimental animals. For these reasons,
it has been proved difficult to identify genetic differences in
humans that influence these common multifactorial condi-
tions. Nevertheless, polymorphisms in several KKS-related
genes have been associated with the risks of developing a
number of renal problems. Thus, the insertion/deletion ACE
polymorphism has been clearly shown to influence diabetic
nephropathy.5 And a polymorphism in the human B2R gene
has been correlated with altered urinary albumin/creatinine
values in diabetic patients.155 Similarly, a polymorphism in
intron 4 of the Nos3 gene has been associated with an
increased risk for nephropathy in patients with either type
1156 or type 2 diabetes.157 Other reports have shown that the
ACE D/D genotype is a risk factor for progression to CRF in
IgA nephropathy.158,159 ADPKD patients with the ACE D/D
genotype have a 5–10 years earlier onset of ESRD than those
with the I/I genotype.160–162 The progression of IgA
nephropathy and ADPKD into ESRD are both influenced
by the Nos3 polymorphism.163 In humans, polymorphisms in
most of the genes in the KKS have also been associated with
the progression of CRF into ESRD, including ACE,164,165
Bdkrb1,166,167 Bdkrb2,167,168 and Nos3.169,170
THERAPEUTIC IMPLICATIONS
Of the presently available drugs, the ACE inhibitors are most
effective in enhancing the KKS, and many of their benefits are
independent of blood pressure lowering. Besides retarding
the decline in renal function, the KKS may be of particular
relevance in the processes of angiogenesis and cardiac
regeneration, following myocardial infarction.171 The recently
developed vasopeptidase inhibitors that inhibit ACE, nepri-
lysin and/or endothelin-converting enzyme, all of which
degrade the kinins, may also prove to be beneficial, when they
become available for clinical use.172 Yet the ACE inhibitors
are not suitable for use in pregnancy because of teratogeni-
city, nor are they recommended in patients with CRF who are
not under dialysis therapy, because they are susceptible to
cardiotoxic hyperkalemia.173 Additionally, some individuals
have to discontinue their usage because of coughing.
At present, no drugs are available that enhance KKS
specifically without affecting the renin–angiotensin–aldoster-
one system.
Kidney International (2009) 75, 1019–1030 1025
M Kakoki and O Smithies: Kinins, nephropathy, and senescence r e v i e w
In principle, KKS-specific antagonists and agonists could
both be useful, although for different purposes. KKS
antagonists could be used for acute life-threatening inflam-
matory conditions including septic shock,174 asthma,175 acute
pancreatitis,176 and attacks in patients with hereditary
angioedema.177 However, because the KKS is important for
retaining renal blood flow and suppressing oxidative stress by
NO and the PGs, long-term usage of KKS antagonists is most
likely to be undesirable. KKS-specific agonists (represented
currently almost exclusively by ACE inhibitors) have, in
contrast, proved effective in long-term usage for the
treatment of senescence-associated renal diseases. Two of
the adverse effects of ACE inhibitors, teratogenicity and
cardiotoxic hyperkalemia, might be avoidable by developing
bradykinin receptor-specific agonists, which would probably
have minimal effects on the renin–angiotensin–aldosterone
system. If the receptor-specific agonists proved not to have
the adverse effects of the ACE inhibitors, they could be useful
for the treatment of diabetes and/or fibrogenic renal diseases
in pregnant women, and in non-dialysed patients with
advanced CRF.
CONCLUSIONS
The KKS affects a variety of physiological and pathophysio-
logical functions in mammals including pain, inflammation,
vascular permeability, oxidative stress, and calcium home-
ostasis.178,179 Of the currently available agents that affect the
KKS, the ACE inhibitors are most important. Thus, although
ACE was initially discovered as a component of renin–
angiotensin–aldosterone system, it has a greater affinity for
bradykinin than for angiotensin I. This accounts for the fact
that ACE inhibitors and the ACE insertion polymorphism
have beneficial effects on a number of fibrogenic kidney
diseases independently of changes in blood pressure and
angiotensin II levels. The importance of the KKS in
renoprotection is now well established. Thus, many studies
have shown that the KKS inhibits the development and
progression of a variety of kidney diseases and senescence
partly by NO and PGs, both of which shift metabolism away
from mitochondrial respiration towards glycolysis. An
interesting possibility is that KKS-specific drugs could be
used to alter the balance between oxidative and non-oxidative
metabolism, thereby providing a new way of decreasing
oxidative stress.
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